Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 8, 2009, Pages 905-912

  Tiplica, G S ^a   Salavastru, C M ^a  

^a Carol Davila School of Medicine   (Romania)

Author keywords

Comparative; Mometasone furoate; Psoriasis vulgaris; Randomized study; Salicylic acid

Indexed keywords

CORTICOSTEROID; MOMETASONE FUROATE; SALICYLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; PSORIASIS AREA SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; ROMANIA; SCORING SYSTEM; SKIN IRRITATION; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; PREGNADIENEDIOLS; PSORIASIS; QUALITY OF LIFE; ROMANIA; SALICYLIC ACID; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67651148327     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03214.x     Document Type: Article

References (17)

1. Langley RG, Krueger GG, Griffiths CEM, Gladman DD. Psoriasis: epidemiology, clinical features and quality of life. Ann Rheum Dis 2005 64 (Suppl. 2 ii 18 23.
2. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152 : 861 867.
3. Fredricsson T, Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatológica 1978 157 : 238 242.
4. Allen BR, Treatment of psoriasis. Prescr J 1993 33 : 183 190.
5. Medansky RS, Bressink R, Cole GW et al. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 Percent. Cutis 1988 42 : 480 485.
6. Katz HI, Tanner DJ, Cuffie CA et al. A comparison of the efficacy and safety of the combination mometasone furoate 0.1% salicylic acid 5% ointment with each of its components in psoriasis. J Dermatol Treat 1998 9 : 151 156.
7. Singh S, Reddy DC, Pandey SS. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol 2000 43 : 61 65.
8. Ware JE Jr., Sherbourne CD. The MOS, 36-Item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care 1992 30 : 473 483.
9. Finlay AY, Khan GK. The Dermatology Life Quality Index: a simple practical measure for routine use. Clin Exp Dermatol 1994 19 : 210 216.
10. http://www.ms.ro/legislatie in vigoare (2008).
11. Drake LA, Ceilley R, Cornelison RL et al. Guidelines of care for psoriasis. J Am Acad Dermatol 1993, 28 : 632 637.
12. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
13. Barton BE, Jakway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991 13 : 251 261.
14. Davies M, Marks RL. Studies on the effect of salicylic acid on normal skin. Br J Dermatol 1976 95 : 187 192.
15. Roberts DL, Marshall R, Marks R. Detection of the action of salicylic acid on the normal stratum corneum. Br J Dermatol 1980 103 : 191 196.
16. Koo J, Cuffie CA, Tanner DJ et al. Mometasone furoate 0.1% - salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998 20 : 283 291.
17. Greaves MW, Hay RJ. Topical corticosteroids. J Roy Coll Phys 1987 21 : 32 34.